Newsletter: January 2025

Newsletter: January 2025

Starting 2025 from a great place...

Last year we made significant strides through innovation and cutting-edge technology such as: launching the state-of-the-art imaging suite; expanding our lung airway models portfolio; publishing several articles depicting the unique advantages of using our kidney nephron models; and continuously supporting the use predictive retina models to move compounds to IND.

Dr Mike Nicholds , our CEO, spoke to Megan Thomas from Drug Discovery World about the industry trends and predictions for drug discovery opportunities for 2025.?The general anticipation is that the market will ramp up through 2025 and the Newcells team is working hard to bring more and better innovative tools to you!

Read the article here

2025 Events & Conferences

We look forward to meeting you in person and online at multiple events throughout 2025 across the world.

Explore here

How is AI Impacting Drug Discovery?

Trending Topics:

We spoke to Dr Colin Brown (Chief Scientific Officer), Dr Valeria Chichagova, PhD , (Director of Technology) and Dr Mike Nicholds (CEO) at Newcells to explore how the industry is using AI, how AI is impacting Newcells’ services and how it might accelerate drug discovery in the coming years.

Listen and read now


Predicting Antibiotics Nephrotoxicity in vitro:

Robust high-throughput nephrotoxicity screening made possible with a unique in vitro model of the proximal tubule cells, expressing high level of Megalin and Cubilin transporters to assess sensitive FDA-approved biomarkers of kidney injury (KIM-1,NGAL and CLUSTERIN).

Download the poster

Meet the Scientists

Anusha Gupta - The scientist behind development of the CBF assay.??

Anusha, the main scientist who developed the CBF assay on the small airway epithelium cell model (SAEC) using the latest technology in our state-of-the-art imaging suite, gives us an insight into what it was like to work on the project.

Read Anusha's story


Case Study??

Find out how we supported a client to confirm their AAV vectors transduced retinal RPE tissue in a dose-dependent manner.

Read the case study

Webinar Series: “Set your Standards High” ??

The “Set your Standards High” webinar series will start again in early 2025 with industry experts addressing toxicity and functional studies and standards in kidney and retina drug discovery.

Register for the webinar

Innovation News

What is brewing in our labs and upcoming in the pipeline through 2025?

View our pipeline

要查看或添加评论,请登录

Newcells Biotech Ltd的更多文章

社区洞察

其他会员也浏览了